Candel Therapeutics signs $50 million at-the-market stock offering agreement with Jefferies
CADL•Candel Therapeutics entered an agreement on November 12, 2026, to sell up to $50 million in common stock through Jefferies. The program adds capacity beyond approximately $50 million already sold under an August 2025 agreement; Jefferies will receive a 3% commission.
1. Offering agreement
Candel Therapeutics entered an agreement on November 12, 2026, to sell up to $50 million in common stock through an at-the-market program with Jefferies. The program adds capacity beyond approximately $50 million already sold under an agreement dated August 14, 2025. Jefferies will receive a 3% commission on gross proceeds and is not obligated to sell a specific number of shares or dollar amount.
